Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease
Background Noncompliance in use of anti-tumor necrosis factor (anti-TNF) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD) can be a factor in medication failure. Few studies have evaluated the contribution of depressive symptoms to medication noncompliance in anti-TNF ther...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2017-12, Vol.62 (12), p.3563-3567 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3567 |
|---|---|
| container_issue | 12 |
| container_start_page | 3563 |
| container_title | Digestive diseases and sciences |
| container_volume | 62 |
| creator | Calloway, Alexis Dalal, Robin Beaulieu, Dawn B. Duley, Caroline Annis, Kimberly Gaines, Lawrence Slaughter, Chris Schwartz, David A. Horst, Sara |
| description | Background
Noncompliance in use of anti-tumor necrosis factor (anti-TNF) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD) can be a factor in medication failure. Few studies have evaluated the contribution of depressive symptoms to medication noncompliance in anti-TNF therapies.
Methods
A retrospective chart review was performed in a single-center tertiary care IBD center for patients with Crohn’s disease and ulcerative colitis starting anti-TNF therapy over a 2-year period. Medication noncompliance was defined as interruption of medication (not filling anti-TNF prescription if injectable or not getting infliximab infusion for 30 days beyond needed date for continuation) due to patient-driven circumstances. Depressive symptoms were evaluated at baseline using the well-validated Patient Health Questionnaire-9 (PHQ-9), with PHQ-9 ≥ 10 indicative of at least moderate depressive symptoms. Statistical analysis was performed using Cox proportional hazards regression controlling for age, sex, psychiatric history, and disease.
Results
A total of 246 patients (75 with ulcerative colitis, 171 with Crohn’s disease) were started on anti-TNF therapy. Seventy-nine patients (32%) had a prior psychiatric diagnosis reported in the medical record. Thirty-three patients (13%) were noncompliant in follow-up. Sixty patients (24%) had at least moderate depressive symptoms at baseline (PHQ ≥ 10). Depressive symptoms at baseline were significantly associated with noncompliance in follow-up (hazards ratio 2.28, CI 1.1–4.6,
p
|
| doi_str_mv | 10.1007/s10620-017-4800-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1954070509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712937632</galeid><sourcerecordid>A712937632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-20eb796076ffc2cea2557478d7f430137b47684f978cbfa1c237030b5a6f4bad3</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhSMEopfCA7BBltiwSRk7iZ0sLy2FSlWpRFlbjjNuXSV2sJ2WvD2-uuVXIC_GHn_naOxTFC8pHFEA8TZS4AxKoKKsW4ByfVRsaCOqkjW8fVxsgPK8p5QfFM9ivAWATlD-tDhgHTSspXxTfDvBOWCM9g7J53Wak58iuQw4WJ3I1iVbpmXygVygDj7aSE6VTvl8dYNBzSu58E77aR6tchqJdeRSJYsuRXJv0w05c2ZU06SyZCXv_D2O5MRGVBGfF0-MGiO-eKiHxZfT91fHH8vzTx_Ojrfnpa6rLpUMsBcdB8GN0UyjYk0jatEOwtQV0Er0teBtbTrR6t4oqlkloIK-UdzUvRqqw-LN3ncO_uuCMcnJRo3jqBz6JUraNTUIaKDL6Ou_0Fu_BJenyxRvBKct57-oazWitM74FJTemcqtoKyrBK9Ypo7-QeU14GS1d2hs7v8hoHvB7p9jQCPnYCcVVklB7tKW-7RlTlvu0pZr1rx6GHjpJxx-Kn7EmwG2B2K-ctcYfnvRf12_A_OftLk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1965761866</pqid></control><display><type>article</type><title>Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Calloway, Alexis ; Dalal, Robin ; Beaulieu, Dawn B. ; Duley, Caroline ; Annis, Kimberly ; Gaines, Lawrence ; Slaughter, Chris ; Schwartz, David A. ; Horst, Sara</creator><creatorcontrib>Calloway, Alexis ; Dalal, Robin ; Beaulieu, Dawn B. ; Duley, Caroline ; Annis, Kimberly ; Gaines, Lawrence ; Slaughter, Chris ; Schwartz, David A. ; Horst, Sara</creatorcontrib><description>Background
Noncompliance in use of anti-tumor necrosis factor (anti-TNF) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD) can be a factor in medication failure. Few studies have evaluated the contribution of depressive symptoms to medication noncompliance in anti-TNF therapies.
Methods
A retrospective chart review was performed in a single-center tertiary care IBD center for patients with Crohn’s disease and ulcerative colitis starting anti-TNF therapy over a 2-year period. Medication noncompliance was defined as interruption of medication (not filling anti-TNF prescription if injectable or not getting infliximab infusion for 30 days beyond needed date for continuation) due to patient-driven circumstances. Depressive symptoms were evaluated at baseline using the well-validated Patient Health Questionnaire-9 (PHQ-9), with PHQ-9 ≥ 10 indicative of at least moderate depressive symptoms. Statistical analysis was performed using Cox proportional hazards regression controlling for age, sex, psychiatric history, and disease.
Results
A total of 246 patients (75 with ulcerative colitis, 171 with Crohn’s disease) were started on anti-TNF therapy. Seventy-nine patients (32%) had a prior psychiatric diagnosis reported in the medical record. Thirty-three patients (13%) were noncompliant in follow-up. Sixty patients (24%) had at least moderate depressive symptoms at baseline (PHQ ≥ 10). Depressive symptoms at baseline were significantly associated with noncompliance in follow-up (hazards ratio 2.28, CI 1.1–4.6,
p
< 0.05).
Conclusion
Depressive symptoms at baseline were associated with medication noncompliance of anti-TNF therapies at follow-up when controlling for age, sex, disease type, and history of psychiatric disease.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-017-4800-y</identifier><identifier>PMID: 29052816</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adalimumab ; Adult ; Aged ; Analysis ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Biochemistry ; Colon ; Crohn's disease ; Depression - complications ; Depression, Mental ; Female ; Gastroenterology ; Hepatology ; Humans ; Inflammatory bowel disease ; Inflammatory Bowel Diseases - drug therapy ; Inflammatory Bowel Diseases - psychology ; Male ; Medication Adherence - psychology ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Necrosis ; Oncology ; Original Article ; Patient compliance ; Patients ; Retrospective Studies ; Transplant Surgery ; Tumor necrosis factor ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor necrosis factor-TNF ; Tumors ; Ulcerative colitis ; Young Adult</subject><ispartof>Digestive diseases and sciences, 2017-12, Vol.62 (12), p.3563-3567</ispartof><rights>Springer Science+Business Media, LLC 2017</rights><rights>COPYRIGHT 2017 Springer</rights><rights>Digestive Diseases and Sciences is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-20eb796076ffc2cea2557478d7f430137b47684f978cbfa1c237030b5a6f4bad3</citedby><cites>FETCH-LOGICAL-c439t-20eb796076ffc2cea2557478d7f430137b47684f978cbfa1c237030b5a6f4bad3</cites><orcidid>0000-0003-3585-9643</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10620-017-4800-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10620-017-4800-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29052816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Calloway, Alexis</creatorcontrib><creatorcontrib>Dalal, Robin</creatorcontrib><creatorcontrib>Beaulieu, Dawn B.</creatorcontrib><creatorcontrib>Duley, Caroline</creatorcontrib><creatorcontrib>Annis, Kimberly</creatorcontrib><creatorcontrib>Gaines, Lawrence</creatorcontrib><creatorcontrib>Slaughter, Chris</creatorcontrib><creatorcontrib>Schwartz, David A.</creatorcontrib><creatorcontrib>Horst, Sara</creatorcontrib><title>Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background
Noncompliance in use of anti-tumor necrosis factor (anti-TNF) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD) can be a factor in medication failure. Few studies have evaluated the contribution of depressive symptoms to medication noncompliance in anti-TNF therapies.
Methods
A retrospective chart review was performed in a single-center tertiary care IBD center for patients with Crohn’s disease and ulcerative colitis starting anti-TNF therapy over a 2-year period. Medication noncompliance was defined as interruption of medication (not filling anti-TNF prescription if injectable or not getting infliximab infusion for 30 days beyond needed date for continuation) due to patient-driven circumstances. Depressive symptoms were evaluated at baseline using the well-validated Patient Health Questionnaire-9 (PHQ-9), with PHQ-9 ≥ 10 indicative of at least moderate depressive symptoms. Statistical analysis was performed using Cox proportional hazards regression controlling for age, sex, psychiatric history, and disease.
Results
A total of 246 patients (75 with ulcerative colitis, 171 with Crohn’s disease) were started on anti-TNF therapy. Seventy-nine patients (32%) had a prior psychiatric diagnosis reported in the medical record. Thirty-three patients (13%) were noncompliant in follow-up. Sixty patients (24%) had at least moderate depressive symptoms at baseline (PHQ ≥ 10). Depressive symptoms at baseline were significantly associated with noncompliance in follow-up (hazards ratio 2.28, CI 1.1–4.6,
p
< 0.05).
Conclusion
Depressive symptoms at baseline were associated with medication noncompliance of anti-TNF therapies at follow-up when controlling for age, sex, disease type, and history of psychiatric disease.</description><subject>Adalimumab</subject><subject>Adult</subject><subject>Aged</subject><subject>Analysis</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biochemistry</subject><subject>Colon</subject><subject>Crohn's disease</subject><subject>Depression - complications</subject><subject>Depression, Mental</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Inflammatory Bowel Diseases - psychology</subject><subject>Male</subject><subject>Medication Adherence - psychology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Necrosis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patient compliance</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Transplant Surgery</subject><subject>Tumor necrosis factor</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><subject>Ulcerative colitis</subject><subject>Young Adult</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1u1TAQhSMEopfCA7BBltiwSRk7iZ0sLy2FSlWpRFlbjjNuXSV2sJ2WvD2-uuVXIC_GHn_naOxTFC8pHFEA8TZS4AxKoKKsW4ByfVRsaCOqkjW8fVxsgPK8p5QfFM9ivAWATlD-tDhgHTSspXxTfDvBOWCM9g7J53Wak58iuQw4WJ3I1iVbpmXygVygDj7aSE6VTvl8dYNBzSu58E77aR6tchqJdeRSJYsuRXJv0w05c2ZU06SyZCXv_D2O5MRGVBGfF0-MGiO-eKiHxZfT91fHH8vzTx_Ojrfnpa6rLpUMsBcdB8GN0UyjYk0jatEOwtQV0Er0teBtbTrR6t4oqlkloIK-UdzUvRqqw-LN3ncO_uuCMcnJRo3jqBz6JUraNTUIaKDL6Ou_0Fu_BJenyxRvBKct57-oazWitM74FJTemcqtoKyrBK9Ypo7-QeU14GS1d2hs7v8hoHvB7p9jQCPnYCcVVklB7tKW-7RlTlvu0pZr1rx6GHjpJxx-Kn7EmwG2B2K-ctcYfnvRf12_A_OftLk</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Calloway, Alexis</creator><creator>Dalal, Robin</creator><creator>Beaulieu, Dawn B.</creator><creator>Duley, Caroline</creator><creator>Annis, Kimberly</creator><creator>Gaines, Lawrence</creator><creator>Slaughter, Chris</creator><creator>Schwartz, David A.</creator><creator>Horst, Sara</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3585-9643</orcidid></search><sort><creationdate>20171201</creationdate><title>Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease</title><author>Calloway, Alexis ; Dalal, Robin ; Beaulieu, Dawn B. ; Duley, Caroline ; Annis, Kimberly ; Gaines, Lawrence ; Slaughter, Chris ; Schwartz, David A. ; Horst, Sara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-20eb796076ffc2cea2557478d7f430137b47684f978cbfa1c237030b5a6f4bad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adalimumab</topic><topic>Adult</topic><topic>Aged</topic><topic>Analysis</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biochemistry</topic><topic>Colon</topic><topic>Crohn's disease</topic><topic>Depression - complications</topic><topic>Depression, Mental</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Inflammatory Bowel Diseases - psychology</topic><topic>Male</topic><topic>Medication Adherence - psychology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Necrosis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patient compliance</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Transplant Surgery</topic><topic>Tumor necrosis factor</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><topic>Ulcerative colitis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Calloway, Alexis</creatorcontrib><creatorcontrib>Dalal, Robin</creatorcontrib><creatorcontrib>Beaulieu, Dawn B.</creatorcontrib><creatorcontrib>Duley, Caroline</creatorcontrib><creatorcontrib>Annis, Kimberly</creatorcontrib><creatorcontrib>Gaines, Lawrence</creatorcontrib><creatorcontrib>Slaughter, Chris</creatorcontrib><creatorcontrib>Schwartz, David A.</creatorcontrib><creatorcontrib>Horst, Sara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Calloway, Alexis</au><au>Dalal, Robin</au><au>Beaulieu, Dawn B.</au><au>Duley, Caroline</au><au>Annis, Kimberly</au><au>Gaines, Lawrence</au><au>Slaughter, Chris</au><au>Schwartz, David A.</au><au>Horst, Sara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>62</volume><issue>12</issue><spage>3563</spage><epage>3567</epage><pages>3563-3567</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Background
Noncompliance in use of anti-tumor necrosis factor (anti-TNF) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD) can be a factor in medication failure. Few studies have evaluated the contribution of depressive symptoms to medication noncompliance in anti-TNF therapies.
Methods
A retrospective chart review was performed in a single-center tertiary care IBD center for patients with Crohn’s disease and ulcerative colitis starting anti-TNF therapy over a 2-year period. Medication noncompliance was defined as interruption of medication (not filling anti-TNF prescription if injectable or not getting infliximab infusion for 30 days beyond needed date for continuation) due to patient-driven circumstances. Depressive symptoms were evaluated at baseline using the well-validated Patient Health Questionnaire-9 (PHQ-9), with PHQ-9 ≥ 10 indicative of at least moderate depressive symptoms. Statistical analysis was performed using Cox proportional hazards regression controlling for age, sex, psychiatric history, and disease.
Results
A total of 246 patients (75 with ulcerative colitis, 171 with Crohn’s disease) were started on anti-TNF therapy. Seventy-nine patients (32%) had a prior psychiatric diagnosis reported in the medical record. Thirty-three patients (13%) were noncompliant in follow-up. Sixty patients (24%) had at least moderate depressive symptoms at baseline (PHQ ≥ 10). Depressive symptoms at baseline were significantly associated with noncompliance in follow-up (hazards ratio 2.28, CI 1.1–4.6,
p
< 0.05).
Conclusion
Depressive symptoms at baseline were associated with medication noncompliance of anti-TNF therapies at follow-up when controlling for age, sex, disease type, and history of psychiatric disease.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29052816</pmid><doi>10.1007/s10620-017-4800-y</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-3585-9643</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2017-12, Vol.62 (12), p.3563-3567 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1954070509 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adalimumab Adult Aged Analysis Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Biochemistry Colon Crohn's disease Depression - complications Depression, Mental Female Gastroenterology Hepatology Humans Inflammatory bowel disease Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - psychology Male Medication Adherence - psychology Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Necrosis Oncology Original Article Patient compliance Patients Retrospective Studies Transplant Surgery Tumor necrosis factor Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF Tumors Ulcerative colitis Young Adult |
| title | Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A38%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Depressive%20Symptoms%20Predict%20Anti-tumor%20Necrosis%20Factor%20Therapy%20Noncompliance%20in%20Patients%20with%20Inflammatory%20Bowel%20Disease&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Calloway,%20Alexis&rft.date=2017-12-01&rft.volume=62&rft.issue=12&rft.spage=3563&rft.epage=3567&rft.pages=3563-3567&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-017-4800-y&rft_dat=%3Cgale_proqu%3EA712937632%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1965761866&rft_id=info:pmid/29052816&rft_galeid=A712937632&rfr_iscdi=true |